New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

Phase 3positiveSKYRIZIRINVOQPositive

AI Analysis

Summary

AbbVie announced positive Phase 3 AFFIRM data showing SKYRIZI demonstrated higher clinical and endoscopic response rates in Crohn's disease patients versus placebo. Open-label extension analyses demonstrated sustained endoscopic outcomes for SKYRIZI and RINVOQ in inflammatory bowel disease.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

AFFIRM Phase 3 data showed higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints

Importance:7/10

Sentiment:

0.75

Phase 3 dataCrohn's diseaseIBDclinical efficacyendoscopic responsesubcutaneousopen-label extension

Related Companies

$ABBV

Read the original article

Published by PR Newswire Biotech on October 11, 2026 5:00 PM

Read Original